VivoSeq
Other

Stent Restenosis

0

Pipeline Programs↗

1

Active Trials↗

1

Companies Involved↗

Stent Restenosis is an early-stage landscape with 0 programs across 1 company. The most active players are Bristol-Myers Squibb.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

88/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

9

clinical trials

Completed7 · 78%
Withdrawn1 · 11%
Not yet recruiting1 · 11%

Clinical Trials

Trial Activity

9 trials

Sirolimus With corTicOsteroid TheraPy for Rapid rEcurrences of Coronary Unexplained In-stent Restenosis
Not yet recruiting·CChina National Center for Cardiovascular Diseases·N/A·NCT06981845·52 enrolled
Tight Glycemic Control During Angioplasty Revascularization Reduces Coronary Stent Restenosis
Completed·UUniversity of Campania Luigi Vanvitelli·N/A·NCT01016509·200 enrolled
A Safety Study of ABI-007 for In-Stent Restenosis
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 2·NCT00093223·76 enrolled
Oral Sirolimus for In-Stent Restenosis
Completed·—·Phase 4·NCT00859183·300 enrolled
STREAMER : STent Restenosis And MEdicaments Release
Completed·HHospices Civils de Lyon·Phase 3·NCT02835586·15 enrolled
Effect of Low-dose vs. High-dose Pitavastatin on In-stent Restenosis
Completed·KKorea University Anam Hospital·Phase 4·NCT02545231·1,000 enrolled
The Effects of Bindarit in Preventing Stent Restenosis
Completed·AAziende Chimiche Riunite Angelini Francesco S.p.A·Phase 2·NCT01269242·148 enrolled
Use of Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 1/2·NCT00124943·112 enrolled
Systemic Rapamycin (Sirolimus) to Prevent In-Stent Restenosis Following Pulmonary Artery Stent Placement
Withdrawn·—·Phase 2·NCT02365415

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)